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DOI 10.1016/j.stem.2007.08.008Reprogramming of somatic cells to the
pluripotent stem cell state may allow
the development of in vitro models of
disease and could provide a mech-
anism for the generation of patient-
specific cells of therapeutic interest.
Reprogramming of mouse fibroblasts
into induced pluripotent stem cells, or
iPS cells, has been achievedwith over-
expression of oct4, sox2, klf4, and
c-myc and drug selection for the reac-
tivation of a marker of pluripotency
(Maherali et al., 2007; Okita et al.,
2007; Takahashi and Yamanaka,
2006; Wernig et al., 2007) (reviewed in
Yamanaka, 2007). Here we show that
n-myc can substitute for c-myc and
that drug selection is dispensable for
reprogramming of fibroblasts to
pluripotent stem cells. We show that
serum-free conditions facilitate re-
programming and that the resulting in-
duced pluripotent stem cells contrib-
ute extensively to teratomas and
chimeras. Our findings greatly simplify
the method for induction of pluripo-
tency and bring it one step closer to
clinical applications.
The iPS cell reprogramming method
is technically very simple, but suffers
from three substantial problems: (1) it
requires that the host cell be geneti-
cally engineered to express a drug
resistance gene driven by a marker
of pluripotency, (2) it requires viral-
mediated integration of transgenes
into the genome, and (3) reactivation
of c-myc in differentiated progeny of
the induced ES-like cells is common
and results in tumor formation (Okita
et al., 2007). A major goal in repro-
gramming is to solve these problems
and achieve the generation of normal
pluripotent stem cells in the absence
of genetic manipulation.We analyzed the gene expression
profiles of pluripotent mouse cells, in-
cluding the inner cell mass of the blas-
tocyst, ES cells, primordial germ cells,
and embryonic germ cells (G. Wei,
R.-F. Yeh, M. Hebrok, and M.R.-S.,
unpublished data). We observed that
n-myc, but not c-myc, is highly up-
regulated in all pluripotent cells. The
study that implicated c-myc in regula-
tion of ES cells relied on the use of
dominant-negative and constitutively
active c-Myc proteins, which would
not functionally discriminate between
the various myc family members (Cart-
wright et al., 2005). n-myc and c-myc
are largely interchangeable (Malynn
et al., 2000), although n-myc has
been reported to be less tumorigenic
than c-myc in in vitro assays of trans-
formation (Malynn et al., 2000). For
these reasons, we decided to test
n-myc in the induction of pluripotency.
We infected rosa26/bgeo;oct4/gfp
mouse embryonic fibroblasts (MEFs)
with lentiviral vectors that lead to the
expression of oct4, sox2, klf4, and
n-myc and tested whether any colo-
nies were observed in the absence of
drug selection, in standard LIF- and
serum-containing ES cell medium. As
early as 6 days postinfection, we ob-
served the appearance of colonies,
all of which stained strongly for alkaline
phosphatase (AP, Figure 1A), a marker
of ES cells. The efficiency of formation
of AP-positive colonies at 11 days
postinfection (82.7 colonies/100,000
cells) was comparable to previous re-
ports (Maherali et al., 2007; Okita
et al., 2007; Wernig et al., 2007). How-
ever, these colonies (Figure 1B) did not
show GFP expression, indicating that
reactivation of the oct4 promoter had
not yet occurred. We picked 16 col-Cell Stem Cell 1,onies, four (25%) of which could be
expanded. With further culture, these
clones progressively displayed GFP
fluorescence (Figure 1C), indicative of
more extensive, although still incom-
plete, reprogramming. Overall, these
clones appeared more unstable than
regular ES cells, and partially differen-
tiated colonies could be observed in
the cultures.
In parallel with the experiments de-
scribed above, we also tested whether
use of serum-free medium would facil-
itate reprogramming. We chose this
approach based on our observation
that ES cells, but not MEFs, tolerate
knockout serum replacement (KSR)
well (data not shown). At 4 days post-
infection, FBS-containing medium was
replaced with KSR-containing me-
dium. Colonies were first observed
at 8 days and counted at 11 days
postinfection. The efficiency of AP+
colony formation in these conditions
was lower than in the presence of
serum (30.7 colonies/100,000 cells).
However, the majority of the colonies
that did develop were small, round,
and compact with well-defined edges
and had reactivated the Oct4/GFP
reporter (Figure 1D, compare colony
morphology with the colonies in-
duced in serum at the same stage,
Figure 1B). The colonies induced in
KSR could easily be identified and
picked based on colony morphology
alone (compare the two colonies on
Figure 1D, left panels). We picked
six colonies 11 days postinfection in
serum-free conditions and estab-
lished three clones (50%) of induced
ES-like cells (Figure 1E) that all main-
tain strong and uniform GFP
expression and excellent ES cell-like
morphology. All three clones areSeptember 2007 ª2007 Elsevier Inc. 245
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CorrespondenceFigure 1. Induction of ES-like Cells by Overexpression of oct4, sox2, klf4, and n-myc in the Absence of Drug Selection
(A) Alkaline phosphatase staining of ES-like colonies induced in the absence of drug selection.
(B) Colonies induced in the presence of serum at 11 days postinfection. No GFP expression was detected.
(C) Clones were picked and expanded in serum-based medium. Patchy GFP expression is seen in some colonies.
(D) Colonies induced in serum-based medium, then replaced with KSR based medium at day 4. Representative colonies from 11 days postinfection
are shown. Note that colonies induced in KSR are smaller andmore compact than the ones induced in serum (compare to Figure 1B). Furthermore, the
majority of ES-like colonies induced in KSR conditions are GFP positive, although some GFP negative colonies are still present (arrow). GFP negative
colonies are less compact and have poorly defined edges.
(E) Clones were picked and expanded in KSR-based medium. Clones have excellent ES-cell colony morphology and maintain strong and uniform
GFP expression.
(F) Cells of all three clones expanded in KSR-based medium were predominantly diploid.
Images in (B), (C), and (D) were taken with a 203 objective, (E) with 103, and (F) with 1003.karyotypically normal diploid cells
(Figure 1F).
To test whether the induced cells
are pluripotent, we injected two of the
clones subcutaneously into immuno-
compromisedmice. Three weeks later,
heterogeneous teratomas were obser-
ved that were similar in appearance to
those resulting from the injection of
control ES cells (Figure 2A). Histological
analysis of teratomas from both
injected clones revealed the presence
of ectoderm-, mesoderm-, and endo-
derm-derived tissues (Figure 2B), indi-
cating that the induced ES-like cells
are indeedpluripotent. To further evalu-246 Cell Stem Cell 1, September 2007 ªate pluripotency of the induced cells,
we injected them into blastocysts to
generate chimeras. Staining for b-ga-
lactosidase, driven by the rosa26 lo-
cus, allowed for the detection of the in-
jected cells and their descendants.
Both iPS cell clones generated E13.5
chimeric embryos at a high frequency
(six of eight embryos for clone 2K1,
and three of four embryos for clone
2K3),with all showing high contribution
from donor cells (Figure 2C). Histologi-
cal analysis of the chimeras revealed
contribution to ectoderm, mesoderm,
and endoderm-derived organs
(Figure 2D), demonstrating that the in-2007 Elsevier Inc.duced cells are indeed pluripotent
stem cells.
Together, these results establish that
pluripotency can be induced in fibro-
blasts in the absence of a drug-select-
able ES cell marker. Interestingly, the
use of serum-free medium appeared
not only to select for reprogrammed
cells but also to accelerate reprogram-
ming. That is, therewere fewer colonies
in serum-free medium but the majority
showed oct4/gfp expression, while no
GFP positive colonies were observed
at the same stage in serum-containing
medium. The ability to induce pluripo-
tency in the absence of drug selection
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CorrespondenceFigure 2. Cells Induced in the Absence of Drug Selection Are Pluripotent
(A) Teratomasgeneratedbyclones2K-1 (middle) and2K-3 (right)werecomparable inweightandappearance to thosegeneratedbycontrolEScells (left).
(B) Teratomas generated by both clones were similar to control ES cells (data not shown) and contained derivatives of all three germ layers, such as
cartilage and gut epithelium (left panel) and neural tissue (right panel).
(C) High-contribution chimera resulting from the injection of clone 2K-1 into blastocysts. Similar results were obtained for clone 2K-3.
(D) Sections showing extensive contribution of injected cells to brain (m, midbrain), heart (v, ventricular myocardium), and gut endoderm (i, intestinal
epithelium).will allow reprogramming of a broad
range of samples, because no a priori
targeting of a drug-selectable cassette
is required. Thiswillmake the technique
broadly accessible to the scientific
community. We have also shown that
a combination of factors different than
the one previously described (Maherali
et al., 2007; Okita et al., 2007; Takaha-
shi and Yamanaka, 2006; Wernig
et al., 2007), with n-myc substituting
for c-myc, is capable of inducing pluri-
potency.Futurestudies shouldaddress
the relative efficacy of n-myc versus
c-myc in reprogramming and whether
n-myc reactivation, like c-myc, results
in tumor formation. The next critical
milestones will be to develop ap-
proaches that induce pluripotency
without viral integration and to translate
thesemethods frommouse to humans.Supplemental Data
Supplemental Data include Experimental
Procedures and can be found with this arti-
cle online at http://www.cellstemcell.com/cgi/
content/full/1/3/245/DC1/.
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